Table 1.

Participant timeline

^*Collection was implemented if the circulating CD34⁺ cells count >20/μl achieved

^†Hodgkin’s and non-Hodgkin’s lymphoma patients received the conditioning regimen of etoposide (600 mg/m²), cytarabine (1200 mg/m²), carboplatin (1500 mg/m²), and melphalan (140 mg/m²) on days −2 to −1. Multiple myeloma patients received the melphalan (200 mg/m²) conditioning regimen on day −1

Abbreviations: 1,25-(OH)₂-D 1,25-dihydroxy-vitaminD, ADRs adverse drug reactions, ALC absolute lymphocyte count, AMC absolute monocyte count, ANC absolute neutrophil count, HC hemoglobin concentration, OM oral mucositis, OS overall survival, PC platelet count, RFS relapse-free survival, SC subcutaneous, WBC white blood cell count